CoreCap Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

CoreCap Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$29.9K	Buy	+263	New	+$21.8K	﹤0.01%	1155
2022 Q3	–	Sell	-416	Closed	-$33K	–	2345
2022 Q2	$33K	Buy	+416	New	+$39.4K	﹤0.01%	1084
2022 Q1	–	Sell	-586	Closed	-$63K	–	2357
2021 Q4	$63K	Buy	+586	New	+$63.9K	﹤0.01%	923

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CoreCap Advisors's HZNP Position: Q4 2022 in Review

CoreCap Advisors opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022: 263 shares worth $29.9K. The stake represents ﹤0.01% of the portfolio and ranks #1155 among its holdings. This is a return to the name: CoreCap Advisors previously reported a position in HZNP as recently as Q2 2022.

CoreCap Advisors first reported a position in HZNP in Q4 2021 and has held it in 3 quarters since. The position peaked at $63K in Q4 2021. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

CoreCap Advisors held 263 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $29.9K as of Q4 2022.
Horizon Therapeutics Public Limited Company Ordinary Shares was a new CoreCap Advisors position in Q4 2022.
Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of CoreCap Advisors's portfolio in Q4 2022, its #1155 holding.
CoreCap Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and has held it in 3 quarters since.
CoreCap Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $63K in Q4 2021.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on CoreCap Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.